Nuwellis (NUWE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$9.0M

Revenue (quarter)

$2.0M

Revenue growth (year over year)

+14.14%

Gross profit (trailing twelve months)

$6.3M

Gross margin

69.69%

Net income (trailing twelve months)

−$11.3M

Net income (quarter)

−$4.8M

Net income growth (year over year)

+61.54%

Net margin

−125.63%

Return on equity

—

EPS (trailing twelve months)

$2,548.34

Book value per share

−$3.56

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

122.41%

Payout ratio

—

Dividend yield

—

Company profile

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

• Is Nuwellis (NUWE) profitable?

  No. Nuwellis reported a net loss of $11.3M over the trailing twelve months.

• How much revenue does Nuwellis (NUWE) make?

  Nuwellis generated $9.0M in revenue over the trailing twelve months, up 14.14% year over year.

• How do I buy stock in Nuwellis (NUWE)?

  NUWE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.